Multiple Myeloma and Plasma Cell Neoplasm, Renal Failure
Conditions
Keywords
stage I multiple myeloma, stage II multiple myeloma, stage III multiple myeloma, renal failure
Brief summary
RATIONALE: Dexamethasone is used to treat multiple myeloma. Drugs used in chemotherapy may stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Plasma exchange is a process in which certain cells are separated from the plasma in the blood by a machine and then only the cells are returned to the patient. Dexamethasone and plasma exchange may be an effective treatment for acute kidney failure caused by multiple myeloma. It is not yet known whether giving dexamethasone and chemotherapy together with plasma exchange is more effective than giving dexamethasone and chemotherapy alone in treating patients with multiple myeloma and acute kidney failure. PURPOSE: This randomized phase III trial is studying dexamethasone, chemotherapy, and plasma exchange to see how well they work compared with dexamethasone and chemotherapy alone in treating patients with newly diagnosed multiple myeloma and acute kidney failure.
Detailed description
OBJECTIVES: Primary * Compare the effect of dexamethasone and cytotoxic chemotherapy with vs without plasma exchange on the likelihood of renal recovery (i.e., dialysis-independent at 100 days) in patients with newly diagnosed multiple myeloma and acute renal failure. Secondary * Compare the overall survival of patients treated with these regimens. * Compare the quality of life of patients treated with these regimens. * Determine the value of renal histology in predicting recovery of renal function in these patients. * Determine the value of serum free light chain assay in determining disease response and renal function recovery in these patients. OUTLINE: This is a randomized, controlled, open-label, multicenter study. Patients are stratified according to planned chemotherapy (vincristine and doxorubicin hydrochloride (VA) or VA-like chemotherapy vs thalidomide-containing chemotherapy vs alkylating agent vs other), frequency of chemotherapy courses (1-3 weekly vs 4 weekly), need for dialysis at randomization (yes vs no), and age (\< 65 years vs ≥ 65 years). Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive oral dexamethasone, at least twice daily, on days 1-4 and 9-12. Patients undergo plasma exchange by cytocentrifugation or plasmafiltration over 2-3 hours in weeks 1 and 2 (7 treatments total; 4 of them in week 1). Patients then receive planned chemotherapy per local clinician on days 17-100. Chemotherapy may continue after 100 days at the discretion of the local clinician. * Arm II: Patients receive dexamethasone and planned chemotherapy as in arm I. Quality of life is assessed at baseline, day 100, and 6 and 12 months. After completion of study treatment, patients are followed at 6 and 12 months and then annually thereafter. Peer Reviewed and Funded or Endorsed by Cancer Research UK PROJECTED ACCRUAL: A total of 280 patients will be accrued for this study.
Interventions
PROCEDUREplasmapheresis
DRUGchemotherapy
DRUGdexamethasone
Sponsors
University of Glasgow
Study design
Allocation
RANDOMIZED
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Newly diagnosed multiple myeloma (MM), meeting ≥ 2 of the following criteria: * Serum or urine\* paraprotein * Bone marrow showing \> 10% plasma cells * Lytic bone lesions NOTE: \*The presence of typical myeloma kidney on renal biopsy is considered equivalent to the demonstration of urine paraprotein by electrophoresis * Acute renal failure attributable to MM, meeting both of the following criteria: * Creatinine \> 5.65 mg/dL OR urine output \< 400 mL/day OR requires dialysis * Unresponsive to treatment with fluids and/or treatment of hypercalcemia with bisphosphonates * No significant intrinsic renal disease unrelated to MM PATIENT CHARACTERISTICS: * Platelet count ≥ 50,000/mm³ * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * ALT and AST ≤ 2.5 times ULN * No contraindications to study medication, including the following: * Active or recent peptic ulcer * Known significant cardiac insufficiency * Allergy to study medications * Not pregnant or nursing * Fertile patients must use effective contraception * No known HIV positivity PRIOR CONCURRENT THERAPY: * No prior chemotherapy for MM * Prior steroid therapy of ≤ 3 days duration for MM allowed
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients alive and dialysis-independent at 100 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | — |
| Glomerular filtration rate (calculated or measured) at 15 and 100 days and at 6 and 12 months | — |
| Proportion of patients alive and dialysis-independent at 6 and 12 months | — |
| Response of myeloma to treatment at 100 days and at 6 and 12 months | — |
| Quality of life | — |
| Change in serum free light chain levels between days 0 and 15 | — |
Countries
United Kingdom
Outcome results
None listed